Colorectal Cancer Biomarkers

Publication Date: February 6, 2017

Key Points

Key Points

Molecular testing to select targeted and conventional therapies for patients with colorectal cancer (CRC) has been the focus of a number of recent studies and is becoming standard practice for management of patients with CRC.

Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).

Diagnosis

...gnosis...

...orectal carcinoma patients being c...


...AF c. 1799 (p.V600) mutational analy...


...tational analysis should be performed in defici...


...should order mismatch repair status tes...


...sufficient evidence to recommend BRAF c.1799 p...


...ufficient evidence to recommend PI...


...insufficient evidence to recommen...


...static or recurrent colorectal carcinoma tiss...


...d paraffin embedded tissue is an accep...


...must use validated colorectal carcinoma molecu...


...nce of molecular biomarker testing for...


...ratories must validate the performance of IHC te...


...ies must provide clinically appropriate turnar...


...IHC biomarker testing in colorectal carcinoma...


...ies should establish policies to ensure e...


Members of the patient’s medical team, i...


...that require send out of tests for trea...


...sts must evaluate candidate specimens for b...


...should use colorectal carcinoma molecula...


...olorectal carcinoma molecular biomarker r...


...al carcinoma molecular biomarker testing report...


...atories must incorporate colorectal carci...


...comes of RAS Mutations and Anti-EGFR T...


...e 2. Concordance Rates Between Primary and Metas...